NCT07117890 Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
| NCT ID | NCT07117890 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Fudan University |
| Condition | Non Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 34 participants |
| Start Date | 2025-02-07 |
| Primary Completion | 2027-02-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 34 participants in total. It began in 2025-02-07 with a primary completion date of 2027-02-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years old 2. histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations. 3. predicted life expectancy ≥ 12 weeks. 4. patient must have measurable disease according to RECIST 1.1 Exclusion Criteria: 1. previos systemic anti-tumor therapy 2. a history of malignant tumors within 2years 3. any severa or poorly controlled systemic disease per investigator's judgement 4. active infections
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07117890 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07117890 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07117890 currently recruiting?
Yes, NCT07117890 is actively recruiting participants. Contact the research team at wangjialei@shca.org.cn for enrollment information.
Where is the NCT07117890 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07117890 clinical trial?
NCT07117890 is sponsored by Fudan University. The trial plans to enroll 34 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.